Industry-Sponsored Symposia
Get up to date with the latest scientific information about chronic spontaneous urticaria (CSU):
-
Watch the symposia from EAACI and EADV 2022 annual congresses
-
Hear from world-leading experts in the field of chronic spontaneous urticaria
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Novartis-sponsored symposium – Chronic Spontaneous Urticaria: Defining the pathway to successful management
In 2022, the European Academy of Allergy and Clinical Immunology (EAACI) celebrated its Annual Congress in Prague, Czech Republic
The Novartis-sponsored satellite symposium that featured at this year’s event focussed on ‘Chronic Spontaneous Urticaria: Defining the pathway to successful management’. This one-hour session was chaired by the renowned Professor Marcus Mauer, providing valuable insight into the evolving treatment landscape, exploration of the pain-points in the patient journey and how best to address them, and optimising patient management to address barriers to successful treatment.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Novartis-sponsored symposium – Targeting complete CSU control: Current state of the art and future perspectives
In 2021, the European Academy of Dermatology and Venereology (EADV) celebrated its 30th Annual Congress
The Novartis-sponsored satellite symposium that featured at this year’s event focussed on ‘Targeting complete CSU control: Current state of the art and future perspectives’. This one-hour session was chaired by Professor Ana Giménez-Arnau, providing valuable insight into the evolving treatment landscape for CSU and the importance of treating the disease until it is gone.
Professor Ana Giménez-Arnau kicked off proceedings by offering insight into some of the major unmet needs in CSU, including real-world data from the AWARE study. This was followed by contributions from Professor Sarbjit Saini and Dr John Reed, who discussed the development of novel anti-immunoglobulin E (anti-IgE) treatments for patients with chronic spontaneous urticaria and other potential therapeutic targets including Bruton’s tyrosine kinase (BTK) and Siglec-8.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Novartis-sponsored satellite symposium: Complete control of chronic spontaneous urticaria – Mission (im)possible?
In July 2021, the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress adopted a ‘hybrid’ format, combining digital and physical elements to produce an exciting and accessible scientific programme
This year’s Novartis company-sponsored virtual symposium, 'Complete control of chronic spontaneous urticaria – Mission (im)possible', was delivered by dermatology experts Professor Marcus Maurer and Professor Zenon Brzoza. In this 45-minute symposium the faculty discuss:
- Why do our patients fail to reach complete control?
- How can targeting IgE contribute to complete control?
Watch the full symposium video below. Use the chaptering buttons within the video to navigate to each section.
Despite the availability of effective therapeutic options and clear diagnostic and treatment algorithms for chronic spontaneous urticaria (CSU), many patients still fail to achieve complete control over their disease. In this symposium, the expert faculty offers insight into why this is the case and explain how the development of novel agents targeting IgE could help improve patient outcomes.
Expert interview
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Mind the PAF: a new route to managing chronic urticaria and allergic diseases?
The 1st European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress took place from 10–12 July 2021.
In 2021, for the first time, the EAACI Annual Congress adopted a “hybrid” format, offering delegates the opportunity to attend either digitally or physically, following the unprecedented success of the digital congress held in 2020. As ever, the congress was packed with unmissable scientific content that centred around the theme of ‘Harmonising research and patient care in allergy, asthma and clinical immunology’. This included a Uriach-sponsored symposium focussed on the role of platelet-activating factor (PAF) in chronic urticaria and allergic rhinitis, which you can watch below.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Novartis-sponsored symposium: Redefining patient care in chronic spontaneous urticaria
The 29th European Academy of Dermatology and Venereology (EADV) Congress “EADV Virtual – New Frontiers in Dermatology and Venereology” took place between the 29–31 October 2020
Despite the challenges of transforming the EADV congress into a virtual event, the organisers remained dedicated to their mission of advancing excellence in clinical care, research, education, and training in the field of dermatology and venereology. Presentations from the Novartis company-sponsored virtual symposium ‘Redefining patient care in chronic spontaneous urticaria' can be found below.
Chair Professor Marcus Maurer, opened the symposium with an introduction to emerging endotypes of chronic spontaneous urticaria (CSU). He was joined by Dr Ana Giménez-Arnau who shared some of the key results from the global AWARE study, and Dr Alexander Eggel provided novel insights on the molecular and cellular level characteristics of different anti-IgE antibody treatments for CSU. Professor Maurer closed the symposium with a summary of the key data from a recent phase IIb clinical trial investigating the anti-IgE antibody, ligelizumab, for the treatment of patients whose disease was inadequately controlled by standard-of-care therapy.
Q&A Session
In this informative session, the expert panel address some of the questions raised by the audience and provide further insight on the topics covered in each of their presentations.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
06–08 June 2020: Bridging innovations into allergy and asthma prevention
The first ever digital European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress was held between 6–8 June 2020. This completely new format was consistent with the aim of the meeting which was to push the boundaries with forward thinking and novel approaches to preventing allergy and asthma worldwide
EAACI encourages tackling allergic diseases and asthma at their root, and key to this was the Novartis company-sponsored virtual symposium ‘Breakthrough in the understanding of the anti-IgE pathway in CSU’, co-chaired by Professor Marcus Maurer and Dr. Alexander Eggel. Professor Maurer begins with an introduction to chronic spontaneous urticaria (CSU) and then hands over to Dr Eggel who speaks in detail about IgE inhibition in CSU, explaining why not all anti-IgEs are born equal. Professor Maurer then describes the clinical implications of this inequality which helps to explain the differential effects of omalizumab and ligelizumab in CSU and asthma.
Following the symposium, the faculty were interviewed on their symposium topics. Discover this additional insight in the expert interview section following the symposium presentations.
Expert interviews
Following the symposium, Professor Maurer and Dr Eggel were asked a series of questions to delve deeper into their presentation topics.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. The EADV 2022 symposium is developed in collaboration with Novartis Pharma AG and expert faculty. All other symposia have been developed in collaboration with Novartis Pharma AG, J. Uriach y Compañía S.A and expert faculty. EPG Health received funding from Novartis Pharma AG in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non- Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country.